NCT02666950 - WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2017

Primary Completion Date

September 25, 2018

Study Completion Date

October 17, 2018

Conditions

Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Isolated Del(5q)Myelodysplastic/Myeloproliferative NeoplasmPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

WEE1 Inhibitor AZD1775

Given PO

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale